Alpine Immune Sciences investor relations material

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. The Company's lead product candidate, ALP-001 (Tocagen's AGS-003), an ADCC-enhancing therapeutic candidate for EGFRvIII+ glioma patients, is being developed in collaboration with Tocagen Inc., under an exclusive license from Transgene S.A.